CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof
AssigneesJiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
InventorsZhuoxiao CAO, Yayuan FU, Cunjing YU, Qiyue HU, Weikang TAO
Life of this patent
Estimating the term…
Abstract
Provided are a CD96 antibody, an antigen-binding fragment and a pharmaceutical use thereof. Further provided are a murine antibody, a chimeric antibody and a humanized antibody comprising the CDR region of the CD96 antibody, and a pharmaceutical composition comprising the CD96 antibody and the antigen-binding fragment thereof, and the use of same as a drug. In particular, provided is a use of a humanized CD96 antibody in the preparation of a drug for treating CD96-related diseases or conditions.
Claims26
A monoclonal antibody or an antigen-binding fragment thereof that specifically binds to human CD96, wherein the monoclonal antibody comprises a heavy chain variable region and a light chain variable region, wherein:
- (i) the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 having the amino acid sequences of SEQ ID NO:
- 16, 17 and 18, respectively, or variants thereof having 1, 2 or 3 amino acid mutations in the respective amino acid sequences;
- and the light chain variable region comprises LCDR1, LCDR2 and LCDR3 having the amino acid sequences of SEQ ID NO:
- 19, 20 and 21, respectively, or variants thereof having 1, 2 or 3 amino acid mutations in the respective amino acid sequences;
- or
- (ii) the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 are shown in having the amino acid sequences of SEQ ID NO:
- 22, 23 and 24, respectively, or variants thereof having 1, 2 or 3 amino acid mutations in the respective amino acid sequences;
- and the light chain variable region comprises LCDR1, LCDR2 and LCDR3 having the amino acid sequences of SEQ ID NO:
- 25, 26 and 27, respectively, or variants thereof having 1, 2 or 3 amino acid mutations in the respective amino acid sequences;
- or
- (iii) the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 having the amino acid sequences of SEQ ID NO:
- 28, 29 and 30, respectively, or variants thereof having 1, 2 or 3 amino acid mutations in the respective amino acid sequences;
- and the light chain variable region comprises LCDR1, LCDR2 and LCDR3 having the amino acid sequences of SEQ ID NO:
- 31, 32 and 33, respectively, or variants thereof having 1, 2 or 3 amino acid mutations in the respective amino acid sequences;
- or
- (iv) the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 having the amino acid sequences of SEQ ID NO:
- 34, 35 and 36, respectively, or variants thereof having 1, 2 or 3 amino acid mutations in the respective amino acid sequences;
- and the light chain variable region comprises LCDR1, LCDR2 and LCDR3 having the amino acid sequences of SEQ ID NO:
- 37, 38 and 39, respectively, or variants thereof having 1, 2 or 3 amino acid mutations in the respective amino acid sequences;
- or
- (v) the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 having the amino acid sequences of SEQ ID NO:
- 40, 41 and 42, respectively, or variants thereof having 1, 2 or 3 amino acid mutations in the respective amino acid sequences;
- and the light chain variable region comprises LCDR1, LCDR2 and LCDR3 having the amino acid sequences of SEQ ID NO:
- 43, 44 and 45, respectively, or variants thereof having 1, 2 or 3 amino acid mutations in the respective amino acid sequences.
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.